Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Pharma News: Vivus, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA)’s Settled Stock & Amgen, Inc. (AMGN)’s Clinical Trial

Editor’s Note: Related tickers: VIVUS, Inc. (NASDAQ:VVUS), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Amgen, Inc. (NASDAQ:AMGN)

Pfizer Elected to Continue Development of Tamper-resistant Painkiller Remoxy – VIVUS, ARNA, ARIA, MNKD, MRK, PFE (FiscalInsider)
Investors in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) saw new options become available this week, for the April 2014 expiration. …VIVUS, Inc. (NASDAQ:VVUS) is on the decline this week, earning a D (“sell”) after receiving a C (“hold”) last week. For Portfolio Grader’s specific subcategory of Equity, VVUS also gets an F. The stock price has dropped 6.1% over the past month, worse than the 1.3% decrease the NASDAQ has seen over the same period of time VIVUS, Inc. (NASDAQ:VVUS) shares plunged -0.81% to $12.23 in last trading session. Stock traded in range of $12.00 – $12.41.

VIVUS, Inc. (NASDAQ:VVUS)

Onyx trials cloud Amgen deal (TheDeal)
A Bloomberg article that ran Aug. 14 cited anonymous sources saying that Amgen, Inc. (NASDAQ:AMGN)‘s $10 billion, $120 per share acquisition of Onyx Pharmaceuticals Inc. was hanging on whether Amgen could see results of a clinical trial for Onyx’s Kyprolis. However, the reference to the study results was ambiguous and left parties tracking the deal trying to figure out which trial the sources were alluding to and whether access to the data could truly be a deal-breaker.

Biotech Stocks in News, VIVUS Inc, Arena Pharmaceuticals Inc, Ariad Pharmaceuticals Inc, MannKind Corporation, Affymax, Pfizer Inc (FiscalInsider)
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is a controversial stock among biotech investors. The bulls believe that increasing rates of global obesity will inevitably trigger more sales of its new weight loss drug, Belviq, which was approved by the FDA last June. However, the bears believe that lingering safety concerns regarding Belviq and the company’s insistence on combining the treatment with other medications could cause problems down the road. Arena shares plunged -0.44% to $6.80 in last trading session. Stock traded in range of $6.75 – $6.91.

Amgen Rating Reiterated by Goldman Sachs Group Inc. (AMGN) (WatchlistNews)
Goldman Sachs Group Inc. reiterated their buy rating on shares of Amgen, Inc. (NASDAQ:AMGN) in a research report released on Friday morning, ARN reports. A number of other firms have also recently commented on AMGN. Analysts at RBC Capital raised their price target on shares of Amgen, Inc. (NASDAQ:AMGN) from $120.00 to $125.00 in a research note to investors on Thursday, August 1st. They now have an outperform rating on the stock.

Investor’s Alert -Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Plug Power Inc (NASDAQ:PLUG), Targacept, Inc. (NASDAQ:TRGT), Inc. (NASDAQ:GTXI) (Techsonian)
LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community. …Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) managed to keep its gain at 1.44% on below normal -average volume of 2.71M shares. The stock settled at $7.06 after floating in a range of $6.95 to $7.13. Significantly, its latest price is at a discount of -14.25% to its 200-day moving average price.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!